Johan Dighed
Director/Board Member chez PROMIMIC AB
Profil
Johan Dighed is currently the Chief Legal Officer & Deputy CEO at Karolinska Development AB.
He is also a Director at Promimic AB, KCIF Fund Management AB, KDev Oncology AB, Modus Therapeutics AB, KD Incentive AB, KDev Investments AB, and AnaCardio AB.
Previously, he worked as the Head-Legal at DSK Hyp AG.
Mr. Dighed graduated from the University of Lund.
Postes actifs de Johan Dighed
| Sociétés | Poste | Début |
|---|---|---|
| KAROLINSKA DEVELOPMENT AB | General Counsel | 01/05/2020 |
| PROMIMIC AB | Director/Board Member | 01/01/2021 |
AnaCardio AB
 AnaCardio AB Pharmaceuticals: MajorHealth Technology AnaCardio AB is a clinical stage biopharmaceutical company based in Stockholm, Sweden. AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility to treat heart failure, a progressive cardiac syndrome affecting more than six million individuals in the US and nearly 100 million worldwide. The Swedish company's unique solution is based on the ghrelin signaling pathway, intended to increase contractility without causing adverse tachycardia, arrhythmia, ischemia, or hypotension. The company was founded by Lars Lund and is currently led by CEO Patrik Strömberg since 2021. | Director/Board Member | - |
KDev Oncology AB
 KDev Oncology AB Miscellaneous Commercial ServicesCommercial Services KDev Oncology AB offers research and development of new cancer treatments. It provides know-how in the field of oncology. The company was founded by David Jern on July 14, 2005 and is headquartered in Solna, Sweden. | Director/Board Member | - |
KDev Investments AB
 KDev Investments AB BiotechnologyHealth Technology KDev Investments AB engages in research, sales, and development in the fields of medicine, biotechnology, pharmaceuticals, and medical technology. It also owns and manages investments of companies in the fields of medicine. Its portfolio will include both early and clinical stage pharmaceutical assets, as well as some technology assets. The company was founded on January 10, 2012 and is headquartered in Solna, Sweden. | Director/Board Member | - |
| KCIF Fund Management AB | Director/Board Member | - |
| KD Incentive AB | Director/Board Member | - |
Modus Therapeutics AB
 Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | Director/Board Member | - |
Anciens postes connus de Johan Dighed
| Sociétés | Poste | Fin |
|---|---|---|
DSK Hyp AG
 DSK Hyp AG Major BanksFinance DSK Hyp AG provides banking and financial services to corporate customers, institutions and private individuals. The bank operates through corporate and institutions division which comprises of merchant banking and securities. The company is headquartered in Frankfurt am Main, Germany. | General Counsel | - |
Formation de Johan Dighed
| University of Lund | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| PROMIMIC AB | Health Technology |
| KAROLINSKA DEVELOPMENT AB | Finance |
| Entreprise privées | 7 |
|---|---|
DSK Hyp AG
DSK Hyp AG Major BanksFinance DSK Hyp AG provides banking and financial services to corporate customers, institutions and private individuals. The bank operates through corporate and institutions division which comprises of merchant banking and securities. The company is headquartered in Frankfurt am Main, Germany. | Finance |
| KCIF Fund Management AB | |
KDev Oncology AB
KDev Oncology AB Miscellaneous Commercial ServicesCommercial Services KDev Oncology AB offers research and development of new cancer treatments. It provides know-how in the field of oncology. The company was founded by David Jern on July 14, 2005 and is headquartered in Solna, Sweden. | Commercial Services |
Modus Therapeutics AB
Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | Health Technology |
| KD Incentive AB | |
KDev Investments AB
KDev Investments AB BiotechnologyHealth Technology KDev Investments AB engages in research, sales, and development in the fields of medicine, biotechnology, pharmaceuticals, and medical technology. It also owns and manages investments of companies in the fields of medicine. Its portfolio will include both early and clinical stage pharmaceutical assets, as well as some technology assets. The company was founded on January 10, 2012 and is headquartered in Solna, Sweden. | Health Technology |
AnaCardio AB
AnaCardio AB Pharmaceuticals: MajorHealth Technology AnaCardio AB is a clinical stage biopharmaceutical company based in Stockholm, Sweden. AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility to treat heart failure, a progressive cardiac syndrome affecting more than six million individuals in the US and nearly 100 million worldwide. The Swedish company's unique solution is based on the ghrelin signaling pathway, intended to increase contractility without causing adverse tachycardia, arrhythmia, ischemia, or hypotension. The company was founded by Lars Lund and is currently led by CEO Patrik Strömberg since 2021. | Health Technology |
